Morgan Stanley Synthetic Biologics, Inc. Transaction History

Morgan Stanley

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Oct 27, 2022	BUY	$1.9 - $2.9 $524 - $800	276 Added 10.2%	2,982 $1,000
Q2 2022 Aug 15, 2022	BUY	$1.9 - $2.9 $524 - $800	276 Added 10.2%	2,982 $1,000
Q1 2022 Oct 27, 2022	SELL	$2.3 - $4.3 $634 - $1,186	-276 Reduced 9.26%	2,706 $1,000
Q1 2022 May 13, 2022	SELL	$2.3 - $4.3 $42,285 - $79,055	-18,385 Reduced 87.17%	2,706 $1,000
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.5 $18 - $31	7 Added 0.03%	21,091 $6,000
Q3 2021 Nov 15, 2021	BUY	$4.3 - $5.8 $90,661 - $122,287	21,084 New	21,084 $10,000

Ticker SYN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,844,100
Market Cap $9.51M
Description
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.